Study of Adebrelimab Combined With Chemoradiotherapy Before Surgery for Esophageal Squamous Cell Carcinoma

What this Trial Is About

Researchers are evaluating the safety and effectiveness of combining adebrelimab with paclitaxel, carboplatin, and short-course radiotherapy before surgery to treat esophageal squamous cell carcinoma ESCC. This study aims to improve the rate of complete tumor removal and survival outcomes for patients with this type of esophageal cancer, as current treatments still leave many patients without ideal results and face high recurrence rates after surgery. The study is a Phase 2 clinical trial focused on integrating immunotherapy with standard treatments to enhance patient outcomes. Participants receive an initial treatment of adebrelimab through intravenous infusion along with nab-paclitaxel and carboplatin in two 21-day cycles. This is followed by a one-week break for radiotherapy over five days. After radiotherapy, patients receive another adebrelimab infusion. Surgery to remove the esophagus esophagectomy is scheduled 4 to 6 weeks after completing the neoadjuvant therapy to assess the tumors response. During the study, patients will be monitored for pathological complete response pCR from enrollment to surgery, as well as other measures such as disease-free survival, overall survival, and adverse events up to 24 months after surgery. Researchers will evaluate surgical outcomes, tumor remission, and treatment safety through clinical exams, imaging, and laboratory tests. Participants are observed closely from the start of treatment through surgery and follow-up to understand how well this combined approach works and how safe it is for patients.

Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma